Mefenamic Acid

Introduction

Mefenamic acid is a member of the non‑steroidal anti‑inflammatory drug (NSAID) class, widely employed for its analgesic, antipyretic, and anti‑inflammatory properties. It is chemically an arylacetic acid derivative with a 2‑methyl‑3‑phenyl‑propionic acid backbone. First synthesized in the early 1960s, mefenamic acid has since become a cornerstone therapeutic agent for managing menstrual pain, mild to moderate acute pain, and other inflammatory conditions. Its pharmacological profile is defined by selective inhibition of cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis. The drug’s clinical relevance is underscored by its broad availability in oral formulations and its well‑characterized safety and efficacy data.

Learning objectives for this chapter include:

• Describe the chemical structure and synthetic pathway of mefenamic acid.
• Explain the pharmacodynamic mechanisms underlying its anti‑inflammatory and analgesic effects.
• Summarize the key pharmacokinetic parameters and factors influencing drug disposition.
• Identify common clinical indications, dosing regimens, and potential adverse effects.
• Apply pharmacological principles to clinical case scenarios involving mefenamic acid.

Fundamental Principles

Core Concepts and Definitions

NSAIDs are a heterogeneous group of compounds that inhibit the cyclooxygenase enzymes COX‑1 and COX‑2, thereby attenuating prostaglandin synthesis and mediating anti‑inflammatory, analgesic, and antipyretic effects. Mefenamic acid, classified as a fenamate, exhibits a moderate COX‑selectivity profile, with a greater affinity for COX‑1. The drug is administered orally and undergoes extensive first‑pass metabolism, resulting in measurable plasma concentrations that correlate with therapeutic effect.

Theoretical Foundations

The therapeutic action of mefenamic acid is predicated on the inhibition of the catalytic activity of COX enzymes. The COX pathway converts arachidonic acid to prostaglandin H₂, which is subsequently metabolized into various prostaglandins and thromboxanes. By competitively blocking the active site of COX, mefenamic acid diminishes prostaglandin synthesis, thereby reducing inflammation, pain, and fever. The degree of COX inhibition is dose‑dependent, and the dissociation constant (K_d) reflects the drug’s affinity for the enzyme.

Key Terminology

• COX‑1 – Constitutive cyclooxygenase involved in gastrointestinal protection and platelet aggregation.
• COX‑2 – Inducible cyclooxygenase expressed during inflammation.
• Half‑life (t_1/2) – Time required for plasma concentration to decrease by 50 %.
• Area under the curve (AUC) – Integral of plasma concentration over time, representing systemic exposure.
• Clearance (CL) – Volume of plasma from which the drug is completely removed per unit time.
• Volume of distribution (V_d) – Hypothetical volume that a drug would need to occupy to produce the observed blood concentration.
• First‑pass metabolism – Pre‑systemic drug degradation occurring in the liver after oral administration.

Detailed Explanation

Pharmacodynamics

Mefenamic acid exerts its therapeutic effects primarily through competitive inhibition of COX enzymes. The drug binds to the heme prosthetic group within the COX active site, preventing access of arachidonic acid. The inhibition is reversible; the drug’s affinity for COX‑1 is higher than for COX‑2, implying a stronger anti‑inflammatory effect at lower concentrations. The resulting decrease in prostaglandin E₂ (PGE₂) levels correlates with analgesia and antipyresis. The inhibition of COX‑1 also accounts for the gastrointestinal side‑effects observed in long‑term therapy.

Pharmacokinetics

Oral absorption of mefenamic acid is rapid, with peak plasma concentrations (C_max) reached within 2–3 h post‑dose. The drug exhibits approximately 50 % bioavailability, a consequence of extensive first‑pass hepatic metabolism. The mean elimination half‑life (t_1/2) ranges between 2.5 and 4 h in healthy adults, though this parameter may extend in patients with hepatic impairment. The plasma concentration–time profile follows a mono‑exponential decline, described by the equation C(t) = C₀ × e^−k_elt, where k_el is the elimination rate constant and C₀ is the initial concentration at time zero.

The area under the plasma concentration–time curve (AUC) is calculated as AUC = Dose ÷ Clearance. Clearance (CL) is influenced by hepatic blood flow and enzymatic activity; thus, variations in liver function can notably alter drug exposure. The volume of distribution (V_d) is moderate, reflecting distribution into extracellular fluid and a limited extent of penetration into adipose tissue. Protein binding is approximately 70 % to plasma albumin, which influences both distribution and elimination.

Factors Affecting Pharmacokinetics

• Age – Elderly patients often exhibit reduced hepatic clearance, potentially prolonging t_1/2.
• Hepatic Function – Impaired liver function decreases first‑pass metabolism, increasing bioavailability and AUC.
• Renal Function – While mefenamic acid is predominantly eliminated hepatically, renal impairment may affect the excretion of metabolites.
• Drug Interactions – Concomitant use of other NSAIDs or drugs that induce or inhibit cytochrome P450 enzymes can modify metabolism.
• Food Intake – High‑fat meals may delay gastric emptying, slightly prolonging T_max but have minimal impact on overall bioavailability.
• Genetic Polymorphisms – Variations in CYP2C9 may influence metabolic rate.

Chemical Structure and Synthesis

Mefenamic acid is the 2‑methyl‑3‑phenyl‑propionic acid, with the chemical formula C₁₃H₁₂NO₂. The synthesis typically involves Friedel–Crafts acylation of aniline with acetic anhydride, followed by methylation and subsequent sulfonation steps to form the final product. The presence of the amino group confers basicity, while the carboxylic acid moiety is essential for COX binding. The drug’s physicochemical characteristics, such as lipophilicity (log P ≈ 2.5), facilitate membrane permeation and oral absorption.

Clinical Significance

Indications

Mefenamic acid is primarily indicated for the relief of menstrual pain (dysmenorrhea), mild to moderate acute pain, and inflammatory conditions such as arthritis when other NSAIDs are contraindicated or poorly tolerated. Its analgesic potency is comparable to low‑dose ibuprofen, and its antipyretic effect is modest relative to paracetamol.

Dosing Regimens

Standard oral dosing for dysmenorrhea involves 500 mg every 6–8 h, not exceeding 2 g per day. For acute pain, 1000 mg may be administered, followed by 500 mg every 6–8 h as needed, with a maximum of 3 g per day. Dose adjustments are advised in hepatic or renal impairment. The drug is typically taken with food to minimize gastrointestinal irritation.

Contraindications and Precautions

Contraindications include hypersensitivity to NSAIDs, active peptic ulcer disease, severe hepatic or renal insufficiency, and pregnancy (particularly in the third trimester due to potential fetal effects). Caution is warranted in patients with cardiovascular disease, as NSAIDs may increase thrombotic risk. Monitoring of gastrointestinal symptoms and renal function is advisable during prolonged therapy.

Adverse Effects

Common adverse events encompass gastrointestinal discomfort, dyspepsia, nausea, and, in rare cases, ulceration. Systemic effects such as hypertension, edema, and fluid retention may arise, particularly with chronic use. Hematologic abnormalities, including thrombocytopenia, are infrequent but have been reported. A small subset of patients may experience hypersensitivity reactions manifesting as rash or anaphylaxis.

Drug Interactions

Mefenamic acid may interact with anticoagulants, increasing bleeding risk due to platelet function inhibition. Concomitant use with corticosteroids may exacerbate gastrointestinal toxicity. Interaction with antihypertensive agents could potentiate hypotension. Additionally, co‑administration with other NSAIDs can lead to additive adverse effects.

Clinical Applications/Examples

Case Scenario 1: Dysmenorrhea Management

A 28‑year‑old woman presents with moderate menstrual cramps unresponsive to low‑dose ibuprofen. She has no history of peptic ulcer disease or cardiovascular disorders. A therapeutic regimen of mefenamic acid 500 mg every 6 h, limited to 2 g per day, is initiated. Symptoms improve within 24 h, and the patient reports minimal gastrointestinal discomfort when the medication is taken with food. Follow‑up confirms sustained relief, and no adverse events are noted over a 3‑month period.

Case Scenario 2: Post‑operative Pain

A 65‑year‑old male undergoes a laparoscopic hernia repair. Baseline liver function tests are within normal limits. Post‑operatively, he experiences moderate pain with an analgesic requirement of 1000 mg mefenamic acid, followed by 500 mg every 6 h as needed. Pain scores decline from 7/10 to 3/10 within 12 h. Hemodynamic parameters remain stable, and no gastrointestinal bleeding occurs. The regimen is discontinued after 72 h, with no residual pain.

Case Scenario 3: Hepatic Impairment

A 55‑year‑old patient with compensated cirrhosis (Child‑Pugh A) requires analgesia for osteoarthritis. Given reduced hepatic clearance, a lower initial dose of 250 mg mefenamic acid twice daily is prescribed. Blood levels are monitored via trough sampling, revealing adequate analgesic effect without accumulation. The patient tolerates therapy, and liver function tests remain unchanged over a 6‑month period.

Problem‑Solving Approach

1. Identify the underlying condition requiring NSAID therapy (pain, inflammation, fever).
2. Assess patient comorbidities (liver/renal function, gastrointestinal risk, cardiovascular status).
3. Choose an appropriate dosing regimen, adjusting for organ dysfunction.
4. Educate the patient on timing relative to meals and potential side‑effects.
5. Implement monitoring protocols (e.g., liver enzymes, renal function, blood pressure).
6. Evaluate therapeutic response and modify therapy as necessary.

Summary / Key Points

• Mefenamic acid is an arylacetic acid NSAID with moderate COX‑selectivity, primarily inhibiting COX‑1.
• The drug is rapidly absorbed orally, with a bioavailability of ~50 % and an elimination half‑life of 2.5–4 h.
• Key pharmacokinetic equations: C(t) = C₀ × e^−k_elt, AUC = Dose ÷ Clearance, t_1/2 = ln2 ÷ k_el.
• Standard dosing for dysmenorrhea is 500 mg every 6–8 h, not to exceed 2 g/day; for acute pain, 1000 mg followed by 500 mg q6–8 h, capped at 3 g/day.
• Contraindications include NSAID allergy, active peptic ulceration, severe hepatic/renal disease, and pregnancy.
• Common adverse effects: gastrointestinal irritation, mild hypertension, fluid retention; rare hematologic or hypersensitivity reactions.
• Drug interactions with anticoagulants, corticosteroids, and antihypertensives necessitate caution.
• Clinical pearls: administer with food to mitigate GI upset, monitor organ function in chronic therapy, consider lower initial dosing in hepatic impairment.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.